The power of protein degradation is now being realized. This innate cellular process is responsible for maintaining protein homeostasis, and we are now exploiting it to break down the proteins that cause disease.
The protein degradation opportunity is immense and reaches across a broad range of disease areas in which new and enhanced treatments are needed. Development of the best, most effective medicines for patients requires extensive biology insight, medicinal chemistry experience, drug discovery expertise and cutting-edge computational tools such as artificial intelligence and machine learning.
Proteovant is leveraging targeted protein degradation to discover and develop transformative medicines for the treatment of patients with life-altering diseases.
We are pursuing this expansive field with speed, scale and intention. Proteovant integrates its foundational degrader portfolio, extensive internal drug hunting expertise, and VantAI’s proprietary ‘Protein Contact First’ deep learning platform to advance novel protein degraders across a range of therapeutic areas. The acquisition of Oncopia Therapeutics in 2020 provided access to sophisticated degrader design capabilities and a robust patented pipeline.
Additionally, we have the strong backing and life sciences expertise of our lead investor, Roivant Sciences.
Our team possesses the scientific knowledge, business acumen and risk-tolerance required to unlock the potential of this promising field of science and deliver transformational therapies for patients.
VP, DMPK
VP, Biology
VP, Discovery Chemistry
VP, Molecular Technology
VP, Program Management
VP, CMC
Frank Torti, MD, Chairman
Vant Chair, Roivant Sciences
Eric Venker, MD
President & Chief Operating Officer, Roivant Sciences
Jonggil Choi
Vice President, Bioinvestment Center, SK. Inc.
Learn More
Roivant Sciences develops transformative medicines faster by building technologies and developing talent in creative ways.
Learn More
SK Inc. boasts globally competitive operating companies in diverse areas such as energy, chemicals, information and communications, materials, logistics and service.
Learn More
Dr. Shaomeng Wang’s lab at the University of Michigan is focused on the discovery and development of novel small molecule therapeutics, including targeting protein-protein interactions.
Learn More
VantAI is the world’s leading engine for the computational design and optimization of targeted protein degraders.
Learn More
Blueprint Medicines and Proteovant Therapeutics entered into a strategic collaboration to advance novel targeted protein degrader therapies. Under the agreement, the companies will discover and advance up to two novel protein degrader target programs into development, with the option to extend to two additional programs.
At Proteovant, we embrace collaboration, internally and externally. We welcome hearing from potential partners, collaborators and parties interested in our platform and pipeline. Please contact us at partnering@proteovant.com to get in touch.
Learn More
Dr. Shaomeng Wang’s lab at the University of Michigan is focused on the discovery and development of novel small molecule therapeutics, including targeting protein-protein interactions.
Drew Fromkin
Chief Executive Officer
Ruby Holder, MBA
Chief Strategy Officer
Zhihua Sui, PhD
Chief Scientific Officer
Tiago Girão, CPA
Chief Financial Officer